Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆
Titel:
Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up ☆
Auteur:
Balar, A.V. Castellano, D.E. Grivas, P. Vaughn, D.J. Powles, T. Vuky, J. Fradet, Y. Lee, J.-L. Fong, L. Vogelzang, N.J. Climent, M.A. Necchi, A. Petrylak, D.P. Plimack, E.R. Xu, J.Z. Imai, K. Moreno, B.H. Bellmunt, J. de Wit, R. O’Donnell, P.H.
Verschenen in:
Annals of oncology
Paginering:
Jaargang 34 () nr. 3 pagina's 289-299
Jaar:
2023
Inhoud:
Uitgever:
Merck Sharp & Dohme LLC., a subsidiary Merck & Co., Inc., The Author(s)